Report Thumbnail
Product Code LP0912710471GQB
Published Date 2023/2/2
English97 PagesGlobal

Global Malaria Vaccines Market Growth 2023-2029Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0912710471GQB◆The Feb 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/2/2
English 97 PagesGlobal

Global Malaria Vaccines Market Growth 2023-2029Pharmaceutical_LifeSciense Market



Abstract


Summary

Malaria Vaccines are used for malaria treatment. Malaria is a severe and widespread disease caused by a parasitic infection by protozoan Plasmodium when transmitted by various species of anopheles mosquitoes.
LPI (LP Information)' newest research report, the “Malaria Vaccines Industry Forecast” looks at past sales and reviews total world Malaria Vaccines sales in 2022, providing a comprehensive analysis by region and market sector of projected Malaria Vaccines sales for 2023 through 2029. With Malaria Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Malaria Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Malaria Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Malaria Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Malaria Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Malaria Vaccines and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Malaria Vaccines.
The global Malaria Vaccines market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
The growing incidence of malaria globally and major players pledging for low profit margin over vaccines is expected to boost growth of the market for malaria vaccines market.
This report presents a comprehensive overview, market shares, and growth opportunities of Malaria Vaccines market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Pre-Erythrocytic Vaccine
Erythrocytic Vaccine
Multi-antigen Vaccine
Segmentation by application
Hospitals
Clinics
Community Centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline Plc
Sanaria Inc
Nobelpharma Co
Sumaya Biotech
GenVec
Key Questions Addressed in this Report
What is the 10-year outlook for the global Malaria Vaccines market?
What factors are driving Malaria Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Malaria Vaccines market opportunities vary by end market size?
How does Malaria Vaccines break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Malaria Vaccines Annual Sales 2018-2029
      • 2.1.2 World Current & Future Analysis for Malaria Vaccines by Geographic Region, 2018, 2022 & 2029
      • 2.1.3 World Current & Future Analysis for Malaria Vaccines by Country/Region, 2018, 2022 & 2029
    • 2.2 Malaria Vaccines Segment by Type
      • 2.2.1 Pre-Erythrocytic Vaccine
      • 2.2.2 Erythrocytic Vaccine
      • 2.2.3 Multi-antigen Vaccine
    • 2.3 Malaria Vaccines Sales by Type
      • 2.3.1 Global Malaria Vaccines Sales Market Share by Type (2018-2023)
      • 2.3.2 Global Malaria Vaccines Revenue and Market Share by Type (2018-2023)
      • 2.3.3 Global Malaria Vaccines Sale Price by Type (2018-2023)
    • 2.4 Malaria Vaccines Segment by Application
      • 2.4.1 Hospitals
      • 2.4.2 Clinics
      • 2.4.3 Community Centers
    • 2.5 Malaria Vaccines Sales by Application
      • 2.5.1 Global Malaria Vaccines Sale Market Share by Application (2018-2023)
      • 2.5.2 Global Malaria Vaccines Revenue and Market Share by Application (2018-2023)
      • 2.5.3 Global Malaria Vaccines Sale Price by Application (2018-2023)
  • 3 Global Malaria Vaccines by Company

    • 3.1 Global Malaria Vaccines Breakdown Data by Company
      • 3.1.1 Global Malaria Vaccines Annual Sales by Company (2018-2023)
      • 3.1.2 Global Malaria Vaccines Sales Market Share by Company (2018-2023)
    • 3.2 Global Malaria Vaccines Annual Revenue by Company (2018-2023)
      • 3.2.1 Global Malaria Vaccines Revenue by Company (2018-2023)
      • 3.2.2 Global Malaria Vaccines Revenue Market Share by Company (2018-2023)
    • 3.3 Global Malaria Vaccines Sale Price by Company
    • 3.4 Key Manufacturers Malaria Vaccines Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Malaria Vaccines Product Location Distribution
      • 3.4.2 Players Malaria Vaccines Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Malaria Vaccines by Geographic Region

    • 4.1 World Historic Malaria Vaccines Market Size by Geographic Region (2018-2023)
      • 4.1.1 Global Malaria Vaccines Annual Sales by Geographic Region (2018-2023)
      • 4.1.2 Global Malaria Vaccines Annual Revenue by Geographic Region (2018-2023)
    • 4.2 World Historic Malaria Vaccines Market Size by Country/Region (2018-2023)
      • 4.2.1 Global Malaria Vaccines Annual Sales by Country/Region (2018-2023)
      • 4.2.2 Global Malaria Vaccines Annual Revenue by Country/Region (2018-2023)
    • 4.3 Americas Malaria Vaccines Sales Growth
    • 4.4 APAC Malaria Vaccines Sales Growth
    • 4.5 Europe Malaria Vaccines Sales Growth
    • 4.6 Middle East & Africa Malaria Vaccines Sales Growth
  • 5 Americas

    • 5.1 Americas Malaria Vaccines Sales by Country
      • 5.1.1 Americas Malaria Vaccines Sales by Country (2018-2023)
      • 5.1.2 Americas Malaria Vaccines Revenue by Country (2018-2023)
    • 5.2 Americas Malaria Vaccines Sales by Type
    • 5.3 Americas Malaria Vaccines Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Malaria Vaccines Sales by Region
      • 6.1.1 APAC Malaria Vaccines Sales by Region (2018-2023)
      • 6.1.2 APAC Malaria Vaccines Revenue by Region (2018-2023)
    • 6.2 APAC Malaria Vaccines Sales by Type
    • 6.3 APAC Malaria Vaccines Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan
  • 7 Europe

    • 7.1 Europe Malaria Vaccines by Country
      • 7.1.1 Europe Malaria Vaccines Sales by Country (2018-2023)
      • 7.1.2 Europe Malaria Vaccines Revenue by Country (2018-2023)
    • 7.2 Europe Malaria Vaccines Sales by Type
    • 7.3 Europe Malaria Vaccines Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Malaria Vaccines by Country
      • 8.1.1 Middle East & Africa Malaria Vaccines Sales by Country (2018-2023)
      • 8.1.2 Middle East & Africa Malaria Vaccines Revenue by Country (2018-2023)
    • 8.2 Middle East & Africa Malaria Vaccines Sales by Type
    • 8.3 Middle East & Africa Malaria Vaccines Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Malaria Vaccines
    • 10.3 Manufacturing Process Analysis of Malaria Vaccines
    • 10.4 Industry Chain Structure of Malaria Vaccines
  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Malaria Vaccines Distributors
    • 11.3 Malaria Vaccines Customer
  • 12 World Forecast Review for Malaria Vaccines by Geographic Region

    • 12.1 Global Malaria Vaccines Market Size Forecast by Region
      • 12.1.1 Global Malaria Vaccines Forecast by Region (2024-2029)
      • 12.1.2 Global Malaria Vaccines Annual Revenue Forecast by Region (2024-2029)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Malaria Vaccines Forecast by Type
    • 12.7 Global Malaria Vaccines Forecast by Application
  • 13 Key Players Analysis

    • 13.1 GlaxoSmithKline Plc
      • 13.1.1 GlaxoSmithKline Plc Company Information
      • 13.1.2 GlaxoSmithKline Plc Malaria Vaccines Product Portfolios and Specifications
      • 13.1.3 GlaxoSmithKline Plc Malaria Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.1.4 GlaxoSmithKline Plc Main Business Overview
      • 13.1.5 GlaxoSmithKline Plc Latest Developments
    • 13.2 Sanaria Inc
      • 13.2.1 Sanaria Inc Company Information
      • 13.2.2 Sanaria Inc Malaria Vaccines Product Portfolios and Specifications
      • 13.2.3 Sanaria Inc Malaria Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.2.4 Sanaria Inc Main Business Overview
      • 13.2.5 Sanaria Inc Latest Developments
    • 13.3 Nobelpharma Co
      • 13.3.1 Nobelpharma Co Company Information
      • 13.3.2 Nobelpharma Co Malaria Vaccines Product Portfolios and Specifications
      • 13.3.3 Nobelpharma Co Malaria Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.3.4 Nobelpharma Co Main Business Overview
      • 13.3.5 Nobelpharma Co Latest Developments
    • 13.4 Sumaya Biotech
      • 13.4.1 Sumaya Biotech Company Information
      • 13.4.2 Sumaya Biotech Malaria Vaccines Product Portfolios and Specifications
      • 13.4.3 Sumaya Biotech Malaria Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.4.4 Sumaya Biotech Main Business Overview
      • 13.4.5 Sumaya Biotech Latest Developments
    • 13.5 GenVec
      • 13.5.1 GenVec Company Information
      • 13.5.2 GenVec Malaria Vaccines Product Portfolios and Specifications
      • 13.5.3 GenVec Malaria Vaccines Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.5.4 GenVec Main Business Overview
      • 13.5.5 GenVec Latest Developments
  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.